| Company | Amount/Round | Lead Investors | Description |
|---|---|---|---|
| Creabilis Therapeutics Italy | $30.6M First | Sofinnova Partners | The money is earmarked for three mid-stage studies of CT327 for psoriasis and dermatitis and CT200, which is being developed for Behcet's Disease. |
| IRX Therapeutics New York | $25M First | Existing investors | The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment. |
| Inimex Pharmaceuticals Canada | $22M Second | Morningside Venture Investments | The company is launching the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and assessing IDR drugs in a range of disease models. |
Creabilis rounds up $30M